09 224 61 11

Lettergrootte: a a a

Wetenschappelijke publicaties

Schwartz GG et al. (2018). Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N. Engl. J. Med.; 379(22):2097-2107.

Armstrong PW et al. (2018). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. JACC Heart Fail.; 6(2):96-104.

Claeys MJ et al. (2017). Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study. Eur. Heart J. Cardiovasc. Pharmacother.; 3(4):189-197.

Pieske B et al. (2017). Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur. Heart J.; 38(15):1119-1127.

Ridker PM et al. (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131

Vardeny O et al. (2016). Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur. J. Heart Fail.; 18(10):1228-1234.

Teerlink JR et al. (2016). Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet; 388(10062):2895-2903.

Teerlink JR et al. (2016). Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J. Am. Coll. Cardiol.; 67(12):1444-14557.

Gheorghiade M et al. (2015). Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA; 314(21):2251-62.

McMurray JJ et al. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004

Jessup M (2014). Neprilysin Inhibition — A Novel Therapy for Heart Failure. N. Engl. J. Med.; 371(11):1062-4.